BioSpace News Archive

OncoSec Medical Incorporated (NASDAQ:ONCS) (the “Company” or “OncoSec”), a company developing late- stage intra-tumoral cancer immunotherapies, today announced that Sandra Aung , Ph.D. joined the Company as Senior Vice President, Chief Clinical Development Officer. Dr. Aung will be responsible for overseeing K

Avadyne Health, the patient liability resolution expert, is pleased to announce it has taken the Patient Financial Advocate Pledge and been awarded the Seal indicating patient excellence in financial communication by the American Association of Healthcare Administrative Management (AAHAM) and the National Patient Financial Advocate Task Force.

- Data demonstrates highly reliable test results with 99.56% specificity and 95.00% sensitivity for patients tested 15 days after symptom onset - Availability of the new IgM blood test on the ARCHITECT® and Alinity™ platforms is part of Abbott’s effort to offer tests across the disease progression of COVID-19 - Abbott’s IgM test will give a more complete picture of where patients are in their recovery [12-October-202

Cambrex, announced the completion of an expansion of its solid form screening and crystallization process development facility in Edinburgh, Scotland.

Interim analyses from GALAXI 1 study presented as an oral presentation at the United European Gastroenterology Week Virtual 2020 Congress

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell therapies for neurodegenerative diseases, announced Stacy Lindborg, Ph.D., Executive Vice President and Head of Global Clinical Research, will deliver a presentation at the 2020 Cell & Gene Meeting on the Mesa, being held virtually October 12-16, 2020.

Avenue Therapeutics, Inc., a company focused on the development of intravenous tramadol for the U.S. market, announced it has received a Complete Response Letter from the U.S. Food and Drug Administration regarding the Company’s New Drug Application for IV tramadol.

Kymera Therapeutics, Inc., a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader therapeutics, will share two key presentations at the 3rd Annual Targeted Protein Degradation Summit on Oct. 14 and 15.

Sunesis Pharmaceuticals, Inc. announced a poster presentation at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics to be held October 24-25, 2020 in a virtual format.

Presentations highlight DecisionDx-Melanoma and DecisionDx-SCC gene expression profile tests for use in cutaneous melanoma and in cutaneous squamous cell carcinoma